Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review.
Ontology highlight
ABSTRACT: Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation
SUBMITTER: Lu LY
PROVIDER: S-EPMC8755267 | biostudies-literature | 2022 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA